seelostherapeutics.com - SEEL Enterprise Value-to-Revenue Multiple

Seelos Therapeutics, Inc. (SEEL) - corporate logo

Seelos Therapeutics (SEEL) repurposes known molecules for the therapy of rare psychiatric pathologies via nasal delivery. The trajectory of the Enterprise Value to revenue ratio on the GURU.Markets chart demonstrates a pivot caused by a funding deficit from major depressive disorder treatments and plans to sell the SLS-002 drug. The current level of reflects the magnitude of the company's valuation relative to its revenue, adjusted for debt structure.

Seelos Therapeutics Inc (SEEL): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

SEEL (Seelos Therapeutics Inc): analytical breakdowns and indicator data

- cash and cash flow indicators:
Fundamental valuation:Seelos Therapeutics, Inc. SEEL
Core merchandise of Seelos Therapeutics, Inc

This indicator measures the total enterprise value, net of debt, per unit of revenue, allowing for an assessment of the market multiple without distortions from capital structure. By analyzing the EV/Revenue chart, an investor can correlate the capitalization rates of Seelos Therapeutics (SEEL) with the efficiency of ESG standard implementation in pharmaceutical production to determine whether the asset is overvalued or possesses growth potential.